ClinicalTrials.gov Identifier: NCT
|
|
- Cory Flowers
- 5 years ago
- Views:
Transcription
1 Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Lines of Therapy: Updated Analysis of CASTOR Maria-Victoria Mateos, Jane Estell, 2 Wolney Barreto, 3 Paolo Corradini, 4 Chang-Ki Min, 5 Eva Medvedova, 6 Ming Qi, 7 Jordan Schecter, 8 Himal Amin, 8 Xiang Qin, 7 William Deraedt, 9 Tineke Casneuf, 9 Christopher Chiu, 7 A. Kate Sasser, 7 Ajay Nooka University Hospital of Salamanca/IBSAL, Salamanca, Spain; 2 Haematology Department, Concord Cancer Centre, Concord Hospital, Concord, NSW, Australia; 3 Hospital Santa Marcelina, Sao Paulo, Brazil; 4 Fondazione IRCCS Instituto Nazionale dei Tumori, Milan, Italy; 5 Seoul St. Mary s Hospital, The Catholic University of Korea, Seoul, South Korea; 6 Oregon Health & Science University, Portland, Oregon, USA; 7 Janssen Research & Development, LLC, Spring House, PA, USA; 8 Janssen Research & Development, LLC, Raritan, NJ, USA; 9 Janssen Research & Development, Beerse, Belgium; Winship Cancer Institute, Emory University, Atlanta, GA, USA. ClinicalTrials.gov Identifier: NCT23634
2 Background Daratumumab Human monoclonal antibody targeting CD38 Direct on-tumor and immunomodulatory MoA -5 Approved As monotherapy for heavily pretreated RRMM by the FDA, EMA, Health Canada, Mexico, and Singapore Combo with standard of care regimens for RRMM after prior therapy (POLLUX and CASTOR) by the FDA Early phase study of daratumumab in combination with bortezomib 6 Deep and durable responses Well tolerated with manageable adverse events CDC, complement-dependent cytotoxicity; ADCC, antibody-dependent cell-mediated cytotoxicity; ADCP, antibody-dependent cell-mediated phagocytosis. MoA, mechanism of action; RRMM, relapsed or refractory multiple myeloma ; FDA, Food and Drug Administration; EMA, European Medicines Agency; CDC, complement-mediated cytotoxicity; ADCC, antibody-dependent cell-mediated cytotoxicity; ADCP, antibody-dependent cellular phagocytosis.. Lammerts van Bueren J, et al. Blood. 24;24. Abstract Overdijk MB, et al. J Immunol. 26;97(3): de Weers M, et al. J Immunol. 2;86(3): Overdijk MB, et al. MAbs. 25;7(2): Krejcik J, et al. Blood. 26;28(3): Mateos MV, et al. Presented at the 2 th Congress of the European Hematology Association; -4 June 25; Vienna, Austria. P275. 2
3 Study Design Multicenter, randomized, open-label, active-controlled, phase 3 study N = 498 Key eligibility criteria RRMM prior line of therapy Prior bortezomib exposure, but not refractory R A N D O M I Z E : (n = 25) Daratumumab (6 mg/kg IV) Every week: Cycles -3 Every 3 weeks: Cycles 4-8 V:.3 mg/m 2 SC on Days, 4, 8, and of Cycles -8 d: 2 mg PO-IV on Days, 2, 4, 5, 8, 9,, and 2 of Cycles -8 (n = 247) V:.3 mg/m 2 SC on Days, 4, 8, and of Cycles -8 d: 2 mg PO-IV on Days, 2, 4, 5, 8, 9,, and 2 of Cycles -8 D only Every 4 weeks: Cycles 9+ Obs only Primary endpoint PFS Secondary endpoints TTP OS ORR, VGPR, CR MRD Stratification factors ISS (I, II, and III) Number of prior lines ( vs 2 or 3 vs >3) Prior bortezomib (no vs yes) Cycles -8: repeat every 2 days Cycles 9+: repeat every 28 days Statistical analyses Planned to enroll 48 patients Primary analysis: ~77 PFS events Premedication for the treatment group consisted of dexamethasone 2 mg, acetaminophen, and an antihistamine, daratumumab, bortezomib and dexamethasone; IV, intravenous; V, bortezomib; SC, subcutaneously; d, dexamethasone; PO, orally; VD, bortezomib and dexamethasone; D, daratumumab; Obs, observation; PFS, progression-free survival; TTP, time to progression; OS, overall survival; ORR, overall response rate; VGPR, very good partial response; CR, complete response; MRD, minimal residual disease; ISS, International Staging System. 3
4 Baseline Demographic and Clinical Characteristics Characteristic (n = 25) (n = 247) Characteristic (n = 25) (n = 247) Age, y Median (range) 75, n (%) ISS staging, n (%) a I II III 64 (3-88) 23 (9) 98 (39) 94 (38) 59 (24) 64 (33-85) 35 (4) 96 (39) (4) 5 (2) Prior lines of therapy, n (%) Median 2 3 >3-3 c 2 (-9) 22 (49) 7 (28) 37 (5) 22 (9) 229 (9) 2 (-) 3 (46) 74 (3) 32 (3) 28 () 29 (89) Creatinine clearance (ml/min), n (%) N >3-6 > (2) 86 (77) (25) 63 (7) Prior ASCT, n (%) 56 (62) 49 (6) Prior PI, n (%) 69 (67) 72 (7) Prior IMiD, n (%) 79 (7) 98 (8) Median time from diagnosis, y (range) Cytogenetic profile, n (%) b N Standard risk High risk 3.87 (.7-2.7) (74) 44 (26) 3.72 (.6-8.6) (73) 5 (27) Prior PI + IMiD, n (%) 2 (45) 29 (52) Refractory to IMiD only, n (%) 74 (3) 9 (36) Refractory to last line of therapy, n (%) 76 (3) 85 (34) ASCT, autologous stem cell transplantation; PI, proteasome inhibitor; IMiD, immunomodulatory drug. a ISS staging is derived based on the combination of serum β2-microglobulin and albumin. b Centralized analysis using next-generation sequencing. Patients with high risk had t(4;4), t(4;6), or del7p abnormalities. c Exploratory. 4
5 Primary Analysis Results The primary endpoint was met at the primary analysis (7.4 months of median follow-up) Hazard ratio (HR):.39; 6% reduction in the risk of progression or death with versus Significantly higher and deeper responses for versus At the primary analysis, the independent data and safety monitoring committee recommended that patients with progressive disease receive daratumumab monotherapy CI, confidence interval; scr, stringent complete response; PR, partial response.. Palumbo A, et al. N Engl J Med. 26;375(8):
6 Objectives Updated outcome of the total patient cohort with longer-term follow-up Outcome in different subgroups of patients according to: Number of prior lines of therapy Minimal residual disease status Cytogenetic abnormalities Updated safety profile 6
7 Updated Efficacy % surviving without progression No. at risk 2-month PFS a 6% 22% HR:.33 (95% CI, ; P <.) Median: 7. months ORR, % CR 26% b ORR = 84% 7% 9% 35% 22% P <. VGPR 62% b CR % ORR = 63% 2% 8% 9% 34% (n = 24) (n = 234) VGPR 29% scr CR VGPR PR Median (range) follow-up: 3. (-2.3) months An additional 7% of patients receiving achieved CR with longer follow up Responses continue to deepen in the group with longer follow-up ITT, intent to treat. Note: PFS: ITT population; ORR: response-evaluable population. a Kaplan-Meier estimate. b P <. for versus. 7
8 PFS: Prior Lines of Treatment prior line 2 to 3 prior lines 2-month PFS a 2-month PFS a % surviving without progression % 25% Median: 7.9 months % surviving without progression Median: 9.8 months 44% 22% Median: 6.3 months No. at risk 3 22 HR:.22 (95% CI,.4-.34; P <.) HR:.5 (95% CI, ; P =.2) is superior to regardless of prior lines of therapy, with greatest benefit observed in prior line 27 4 a Kaplan-Meier estimate. 8
9 PFS by Prior Bortezomib Exposure: Prior Line Population % surviving without progression No prior bortezomib Prior bortezomib No prior bortezomib Prior bortezomib No. at risk No prior bortezomib - No prior bortezomib Prior bortezomib - Prior bortezomib provides treatment benefit regardless of prior bortezomib exposure 9
10 Time From Last Line of Therapy to Study Treatment of > or 2 >2 2 HR:.27 (95% CI,.7-.43; P <.) 2-month PFS a HR:.34 (95% CI, ; P <.) 2-month PFS a % surviving without progression % 32% Median: 9.4 months % surviving without progression % 3% Median:.3 months Median: 5.2 months No. at risk No. at risk is superior to regardless of time since last therapy a Kaplan-Meier estimate.
11 ORR by Prior Lines a prior line 2 to 3 prior lines P =.4 P =.22 ORR, % CR: 36% b ORR = 9% CR: 5% VGPR: 75% c ORR = 74% (n = 9) (n = 9) VGPR: 42% scr CR VGPR PR ORR, % CR: 9% d ORR = 79% VGPR: 52% c CR: 7% ORR = 58% 6 37 (n = 99) (n = ) VGPR: 2% scr CR VGPR PR More patients achieve a deeper response with after prior line of treatment a Response-evaluable population. b P =.6 for vs. c P <. for vs. d P =.33 for vs.
12 MRD rates by prior lines of therapy ITT (N = 498) prior line (n = 235) *** ** ** *** ** NS 25 5.X 4.3X 5.5X 6.6X 4.6X 3.2X MRD-negative rate, % Sensitivity MRD was evaluated by ClonoSEQ-NGS-based assay in a central lab at three sensitivity thresholds, for patients with suspected CR and also for patients who maintain CR at C9 and C5 MRD-negative rates for were 3-fold higher across all thresholds MRD-negative rate, % threshold ***P <.; **P <.; NS, not significant. P values calculated using likelihood-ratio chi-square test. MRD-negativity rate = proportion of patients with negative MRD test results at any time during treatment. 2
13 PFS: MRD Status ( 5 ) ITT prior line MRD negative MRD negative MRD negative MRD negative % surviving without progression MRD positive % surviving without progression MRD positive MRD positive MRD positive MRD negativity is associated with better outcomes 3
14 PFS: Cytogenetic Risk in All Evaluable Patients a % surviving without progression No. at risk std risk std risk high risk high risk std risk high risk std risk high risk High risk b Standard risk Median PFS, mo HR (95% CI) P value ORR, % P value n = 44 n = 23 n = 35 NR (.2-.43) <. n = 8 n = n = 5 Median PFS, mo HR (95% CI) P value.49 ( ).67 n = 44 n = 47 ORR, % P value.39 improves outcomes regardless of cytogenetic risk NR, not reached. a ITT/Biomarker risk evaluable analysis set. b Central next-generation sequencing. High-risk patients had any of t(4;4), t(4;6), or del7p. Standard-risk patients had an absence of high-risk abnormalities. 4
15 OS ITT OS events 8 37 (5%) in % surviving patients (24%) in OS HR for versus by prior lines: prior line = HR:.42 (95% CI,.9-.93) 2-3 prior line = HR:.54 No. at risk HR:.63 (95% CI, ) (95% CI, ) Curves are beginning to separate, but OS data are immature Median OS was not reached; results did not cross the prespecified stopping boundary. 5
16 Most Common TEAEs (All Patients): Updated Analysis (n = 243) (n = 237) Hematologic, n (%) All-grade Grade 3/4 All-grade Grade 3/4 25% a 5% a 25% a 5% a Thrombocytopenia 45 (6) (45) 5 (44) 78 (33) Anemia 67 (28) 36 (5) 75 (32) 38 (6) Neutropenia 45 (9) 32 (3) 23 () (5) Lymphopenia 32 (3) 24 () 9 (4) 6 (3) Nonhematologic, n (%) Peripheral sensory neuropathy 2 (49) (5) 9 (38) 6 (7) Diarrhea 83 (34) 9 (4) 53 (22) 3 () Upper respiratory tract infection 72 (3) 6 (3) 43 (8) (.4) Cough 66 (27) 3 (3) Fatigue 53 (22) 2 (5) 58 (25) 8 (3) Pneumonia 33 (4) 22 (9) 28 (2) 23 () Hypertension 22 (9) 6 (7) 8 (3) 2 (.8) Grade 3/4 TEAEs: 79% of patients versus 63% of patients Discontinuations due to TEAEs: 9% of patients versus 9% of patients b No new IRRs; incidence remains stable with longer follow up (45%) TEAE, treatment-emergent adverse event; IRR, infusion-related reaction. a Common TEAEs listed are either 25% all grade OR 5% grade 3/4. b arm treated for 8 cycles and arm treated until progressive disease, per protocol. 6
17 Conclusions PFS benefit continues to be maintained with over time is superior to regardless of prior lines of therapy Largest magnitude of benefit with is observed in patients with prior line of therapy 78% reduction in risk of progression or death for versus More patients in achieved deeper responses with longer follow-up Higher CR and MRD-negative rates MRD negativity translated into longer PFS is superior to regardless of cytogenetic risk or time since last therapy No new safety signals were reported These data further support the use of this newly approved regimen of in RRMM, with most benefit in patients with prior line of therapy 7
18 Acknowledgments Patients who participated in this study Investigators Data and safety monitoring committee Staff members involved in data collection and analyses David Soong and Christopher Velas 6 countries This study was funded by Janssen Research & Development, LLC Medical writing and editorial support were provided by Jason Jung, PhD, of MedErgy, and were funded by Janssen Global Services, LLC 8
ClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients With to 3 Prior Lines of Therapy Based on
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationClínica Universidad de Navarra-CIMA, IDISNA, Pamplona, Spain. ClinicalTrials.gov Identifiers: NCT and NCT
Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated With Daratumumab in Combination With Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationDaratumumab: Mechanism of Action
An Open-label, Randomised, Phase 3 Study of Daratumumab, Lenalidomide, and Dexamethasone (D) Versus Lenalidomide and Dexamethasone () in Relapsed or Refractory Multiple Myeloma (RRMM): POLLUX* Meletios
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationSTUDY DESIGN. VMP 6-week cycles, total of 9 cycles. Figure 2. Alcyone study design. Countries housing study sites are shaded in gold.
TPS8608 A Randomized Open-label Study of Bortezomib, Melphalan, And Prednisone (VMP) Versus Daratumumab () Plus VMP in Patients With Previously Untreated Multiple Myeloma (MM) Who Are Ineligible for High-dose
More informationCity of Hope, Duarte, CA, USA; 11 Columbia University Medical Center, New York, NY, USA. 1
Open-label, Multicenter, Phase 1b Study of Daratumumab in Combination With Pomalidomide and Dexamethasone in Patients With 2 Lines of Prior Therapy and Refractory or Relapsed and Refractory Multiple Myeloma
More informationDARA Monotherapy Studies
Usmani, SZ. Blood. 26. http://dx.doi.org/.82/blood-26-3-752. Lokhorst HM, et al. N Engl J Med. 25;373(3):27-29. Lonial S, et al. Lancet. 25. I DARA Monotherapy Studies Baseline Characteristics Median (range)
More informationClinicalTrials.gov Identifier: NCT
Subcutaneous Delivery of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): PAVO, an Open-label, Multicenter, Dose Escalation Phase 1b Study Ajai Chari, 1 Hareth Nahi, 2 Maria-Victoria
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationPhase 2 Study of Daratumumab (DARA) in Patients with 3 Lines of Prior Therapy or Double Refractory Multiple Myeloma: MMY2002 (Sirius)*
Phase 2 Study of Daratumumab (DARA) in Patients with 3 Lines of Prior Therapy or Double Refractory Multiple Myeloma: 54767414MMY2002 (Sirius)* Sagar Lonial, 1 Brendan Weiss, 2 Saad Usmani, 3 Seema Singhal,
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationASCO Analyst & Investor Webcast. June 1, 2018
ASCO Analyst & Investor Webcast June 1, 2018 June 1, 2018 NASDAQ: BLUE Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information
More informationAntibodies are a standard part of first relapse management in multiple myeloma (MM): Yes
Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes Ajay Nooka, MD MPH FACP Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationHighlights in multiple myeloma
3 CONGRESS HIGHLIGHTS Highlights in multiple myeloma P. Vlummens, MD SUMMARY Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment
More informationAbstract. Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, USA; 2 Hospital-12-de-Octubre, Madrid, Spain; 3
Daratumumab, Carfilzomib, and Dexamethasone (D-Kd) in Lenalidomiderefractory Patients with Relapsed Multiple Myeloma (MM): Subgroup Analysis of MMY11 Chari A, 1* Martinez-Lopez J, 2 Mateos M-V, 3 Bladé
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationCost-effectiveness of Daratumumab (Darzalex ) for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.
Cost-effectiveness of Daratumumab (Darzalex ) for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma. The NCPE has issued a recommendation regarding the cost-effectiveness of
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationAn Open-label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma
An Open-label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma Philippe Moreau, MD; Maria-Victoria Mateos, MD, PhD; Joan Bladé,MD; Lotfi
More informationNovel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma
Novel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma Ravi Vij, MD MBA Professor of Medicine Washington University School of Medicine Section of Stem Cell Transplant
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationElotuzumab is a humanized monoclonal antibody designed to treat multiple myeloma (MM)
A Phase 2 Study of in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/ Refractory Multiple Myeloma: Updated Results Paul G. Richardson, 1,2 Sundar Jagannath, 2,3 Philippe
More informationNovel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors
Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Antonio Palumbo M.D. Takeda Pharmaceuticals International AG Introduction Multiple genetically-distinct subclones
More informationPomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. Lacy MQ et al. J Clin Oncol 2009;27(30):
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma Lacy MQ et al. J Clin Oncol 2009;27(30):5008-14. Introduction A curative therapy for multiple myeloma (MM) does
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationDaratumumab: Uncovering a novel mechanism of action for an approved antibody therapy
Daratumumab: Uncovering a novel mechanism of action for an approved antibody therapy Dr. Kate Sasser, PhD Corporate VP, Translational Research December 14 th, 2017 CD38 is ubiquitously expressed in Myeloma
More informationDaratumumab is a first-in-class anti-cd38 monoclonal antibody that has been
1995 2017 RESEARCH & LEADERSHIP Y E A S R JANUARY 2017 Exclusive Coverage of the American Society of Hematology Annual Meeting 2016 SAN DIEGO, CALIFORNIA DECEMBER 3-6 Subcutaneous Daratumumab Safe and
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationMULTIPLE MYELOMA. The clonoseq Assay can predict progressionfree survival in myeloma patients
MULTIPLE MYELOMA With current therapies, complete response (CR) is reached in 3-5% of multiple myeloma () patients. 1 However, most of these patients will experience relapse due to the persistence of residual
More informationA Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Jatin J. Shah, MD 1, Edward A. Stadtmauer, MD 2, Rafat
More informationMultiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D.
Multiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D. Multiple Myeloma Facts Second most prevalent hematologic neoplasm Nearly 24, new cases diagnosed in the US per year and 11, worldwide
More informationTherapie des Multiplen Myeloms Alles im Fluss? Peter Neumeister, MD Division Hematology Medical University Graz
Therapie des Multiplen Myeloms Alles im Fluss? Peter Neumeister, MD Division Hematology Medical University Graz 15.6.218 Newly Diagnosed Multiple Myeloma Transplant Eligible NDMM TE VCD is preferable to
More informationA Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Jatin J. Shah, MD 1, Edward A. Stadtmauer, MD 2, Rafat
More informationPhase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Phase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Jatin J Shah, MD, Sheeba Thomas, MD, Donna Weber, MD, Michael Wang, MD, Raymond Alexanian, MD, Robert
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationThe TOURMALINE-MM1 study: results and expert insights
The TOURMALINE-MM1 study: results and expert insights Professor Faith Davies UAMS Myeloma Institute, Arkansas, USA This educational meeting was organised and fully funded by Takeda UK Ltd. Takeda medicines
More informationBest of ASH 2017 DR. BRIAN DURIE. Brian GM Durie, MD Thursday, January 11, 2018
Best of ASH 2017 DR. BRIAN DURIE Brian GM Durie, MD Thursday, January 11, 2018 1 ASH Overview 2017 Total myeloma abstracts: 981 Important/Interesting: oral ~40 posters ~60 100 2 Which abstracts impact
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationTREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE
TREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE PRESENTED BY: Pooja Chaukiyal MD Hematologist/Oncologist New York Oncology Hematology Albany, NY April 16, 2016 Background The prognosis for patients
More informationUK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook
UK Myeloma Research Alliance Myeloma XII study (ACCoRD): Augmented Conditioning & Consolidation in Relapsed Disease UK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook Sponsor ID: Pending
More informationProteasome inhibitor (PI) and immunomodulatory drug (IMiD) refractory multiple myeloma is associated with inferior patient outcomes
Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor
More informationMULTIPLE MYELOMA. The clonoseq Assay can predict progressionfree survival in myeloma patients
MULTIPLE MYELOMA With current therapies, complete response (CR) is reached in 3-5% of multiple myeloma () patients. 1 However, most of these patients will experience relapse due to the persistence of residual
More informationDigging Deeper Updates from ASH Interviews with Dr. Berinstein, Dr. Cheson, Dr. Connors, Dr. LeBlanc, Dr. Owen, and Dr.
P E R S P E C T I V E S I N O N C O L O G Y Number 3 April 217 Digging Deeper Updates from ASH 216 INSIDE THIS ISSUE MULTIPLE MYELOMA Novel Agent and New Therapy Combinations Provide Effective Treatment
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationGli anticorpi monoclonali nel trattamento del mieloma multiplo recidivato/refrattario: anti CD38 e SLAMF7. Alessandro Corso
Gli anticorpi monoclonali nel trattamento del mieloma multiplo recidivato/refrattario: anti CD38 e SLAMF7 Alessandro Corso Immunological aspects of cancer chemotherapy Zitvogel et al. Nature Reviews Immunology,
More informationDose-Dependent Efficacy of Daratumumab as Monotherapy in Patients with Relapsed or Refractory Multiple Myeloma
Dose-Dependent Efficacy of Daratumumab as Monotherapy in Patients with Relapsed or Refractory Multiple Myeloma Henk Lokhorst, Jacob Laubach, Hareth Nahi, Torben Plesner, Peter Gimsing, Markus Hansson,
More informationFOR IMMEDIATE RELEASE
FOR IMMEDIATE RELEASE FOR UK MEDICAL AND TRADE MEDIA ONLY Takeda Presents Data from TOURMALINE-MM1 Study for Ixazomib, the First and Only Once-Weekly Oral Proteasome Inhibitor Studied in Phase III Clinical
More informationPhase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial
Phase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial Jonathan L. Kaufman, Todd Zimmerman, Cara A. Rosenbaum, Anuj Mahindra,
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationMultiple Myeloma New Trials and New Drugs. Rafat Abonour, M.D.
Multiple Myeloma New Trials and New Drugs Rafat Abonour, M.D. Treatment Combinations Then and Now NEW VD Rev/Dex CyBorD VTD VRD CDR SCT VD/VRD Lenalidomide Bortezomib Bortezomib Lenalidomide Thalidomide
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationBest of ASH 2018: Myeloma
Best of ASH 2018: Myeloma Brandi Reeves, MD Assistant Professor Division of Hematology-Oncology University of North Carolina 1/23/2019 Learning Objectives Understand the preferred frontline treatment options
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationIMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
More informationLiving Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern
Living Well with Myeloma Teleconference Series Thursday, March 24 th 216 4: PM Pacific/5: PM Mountain 6: PM Central/7: PM Eastern Speakers Dr. Brian Durie, IMF Chairman Cedars Sinai Samuel Oschin Cancer
More informationData featured as a Late-Breaking Abstract at ASH 2018 (Abstract #LBA-2)
Media Inquiries: Brian Kenney Phone: 1-215-620-0111 Satu Glawe Phone: +49 172 294 6264 Investor Relations: Christopher DelOrefice Phone: 1-732-524-2955 Lesley Fishman Phone: 1-732-524-3922 U.S. Medical
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationMethods: Studies included in the analysis
Efficacy and safety of long-term ixazomib maintenance therapy in patients with newly diagnosed multiple myeloma not undergoing transplant: An integrated analysis of four phase 1/2 studies Meletios A. Dimopoulos,
More informationDARZALEX. daratumumab PRODUCT INFORMATION. DARZALEX (daratumumab) 20 mg/ml concentrate for solution for infusion. CAS Registry Number:
NAME OF THE MEDICINE DARZALEX daratumumab PRODUCT INFORMATION DARZALEX (daratumumab) 20 mg/ml concentrate for solution for infusion. CAS Registry Number: 945721-28-8. DESCRIPTION Daratumumab is an immunoglobulin
More informationDisclosures. Consultancy, Research Funding and Speakers Bureau: Celgene Corporation, Millennium, Onyx, Cephalon
Pomalidomide With or Without Low-dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Outcomes in Patients Refractory to Lenalidomide and Bortezomib Ravi Vij 1, Paul G. Richardson
More informationOncology Highlights ASCO 2011 MULTIPLE MYELOMA
Oncology Highlights ASCO 211 MULTIPLE MYELOMA July 211 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist, Mayo Clinic Arizona Disclosures
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationDisclosures. Membership of Advisory Committees: Research Support/ PI: Celgene Corporation Millennium Pharmaceuticals Johnson & Johnson
Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That
More informationShould we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain
Should we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain Should we treat some patients with Stage I MM? Len-dex is a promising and atractive option
More informationTerapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationMultiple Myeloma. Dr. Janet MacEachern BA, MD, FRCP(C) Grand River Regional Cancer Center Kitchener, Ontario
Multiple Myeloma Dr. Janet MacEachern BA, MD, FRCP(C) Grand River Regional Cancer Center Kitchener, Ontario Disclosures Relationships with financial sponsors: Grants/Research Support: n/a Speakers Bureau/Honoraria:
More informationBackground. Approved by FDA and EMEA for CLL and allows for treatment without chemotherapy in all lines of therapy
Updated Efficacy and Safety From the Phase 3 RESONATE-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Abstract
More informationDARZALEX. daratumumab NEW ZEALAND DATA SHEET
1 PRODUCT NAME DARZALEX daratumumab NEW ZEALAND DATA SHEET DARZALEX (daratumumab) 20 mg/ml concentrate for solution for infusion. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5 ml vial contains 100
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationRegimen Protocols IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone
Regimen Protocols IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone Constituents of Regimen: ixazomib, lenalidomide, dexamethasone Other Names of Regimen Constituents and Unique Ingredient Identifier
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationInduction Therapy in Transplant Eligible MM 2 December Tontanai Numbenjapon, M.D.
Induction Therapy in Transplant Eligible MM 2 December 2017 Tontanai Numbenjapon, M.D. What we need from induction therapy in NDMM Depth of response: MRD-negative, scr, CR Longest response Acceptable toxicity
More informationMultiple Myeloma Brian Berryman, M.D. March 8 th, 2014
Multiple Myeloma 2014 Brian Berryman, M.D. March 8 th, 2014 Kyle, R. A. et al. Blood 2008;111:2962-2972 Updates in Multiple Myeloma CCO Independent Conference Coverage of the 2013 Annual Meeting of
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationDaratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
The new england journal of medicine Original Article The authors affiliations are listed in the Appendix. Address reprint requests to Dr. Palumbo at the Department of Hematology, University of Turin, Via
More informationH. Lee Moffitt Cancer Center and Research Institute, University of California, San Francisco & Tisch Cancer Institute, Mount Sinai School of Medicine
Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study Rachid Baz, Thomas
More informationFOR EU TRADE AND MEDICAL MEDIA ONLY
Media Inquiries: Natalie Buhl Mobile: +353 (0)85-744-6696 Email: nbuhl@its.jnj.com Investor Relations: Lesley Fishman Phone: +1-732-524-3922 New Data for Darzalex (daratumumab) Presented at ASH 2017 Show
More informationClaPD (Clarithromycin/[Biaxin ], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma
ClaPD (Clarithromycin/[Biaxin ], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Tomer Mark 1, Angelique Boyer 1, Adriana Rossi 1, Manan Shah 1, Roger Pearse 1, Faiza Zafar
More informationJanssen Hematologic Malignancy Portfolio
Janssen Hematologic Malignancy Portfolio Recorded Webcast: Update for Analysts and Investors January 216 Oncology 1 Safe Harbor Statement This webcast contains "forward-looking statements" as defined in
More informationModel-Informed Drug Development (MIDD) for Ixazomib, an Oral Proteasome Inhibitor
Model-Informed Drug Development (MIDD) for Ixazomib, an Oral Proteasome Inhibitor Neeraj Gupta, Michael J. Hanley, Paul M. Diderichsen, 2 Huyuan Yang, Yeamin Huh, Alice Ke, 4 Zhaoyang Teng, Richard Labotka,
More informationIs Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD
Is Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD Ajai Chari, MD Associate Professor of Medicine Director of Clinical Research Multiple Myeloma Program Mount Sinai Medical Center
More informationMillennium Pharmaceuticals, Inc., Cambridge, MA; 11 Dana-Farber Cancer Institute, Boston, MA
Phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma Shaji K. Kumar,
More informationTreatment of elderly patients with multiple myeloma
Treatment of elderly patients with multiple myeloma Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Improved survival in multiple myeloma and the impact
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationCurrent management of multiple myeloma. Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School
Current management of multiple myeloma Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School JorgeJ_Castillo@dfci.harvard.edu Multiple myeloma MM is a plasma cell neoplasm characterized
More informationPhase I/II Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma
Phase I/II Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma Jatin J Shah, MD 1, Robert Z. Orlowski, MD, PhD 1, Raymond Alexanian, MD 1, Michael
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Daratumumab (Darzalex) for Multiple Myeloma October 5, 2017
pan-canadian Oncology Drug Review Final Clinical Guidance Report Daratumumab (Darzalex) for Multiple Myeloma October 5, 2017 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationManaging Major Adverse Events in Relapsed/Refractory Multiple Myeloma
Welcome to Managing Myeloma. I am Dr. Ajay Nooka. In today's presentation, I will discuss managing major adverse events in relapsed/refractory multiple myeloma. In this video, I will provide you with information
More informationBackground CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.
Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller
More informationModified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
ORIGINAL ARTICLE 218 Oct 26. [Epub ahead of print] https://doi.org/1.394/kjim.218.144 Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
More informationLong-term ixazomib maintenance is tolerable and improves depth of response following ixazomiblenalidomide-dexamethasone
Long-term ixazomib maintenance is tolerable and improves depth of response following ixazomiblenalidomide-dexamethasone induction in patients with previously untreated multiple myeloma (MM): Phase 2 study
More information